DeepCure

DeepCure developed an AI platform designed to search the enormous chemical space with high accuracy. By combining the power of its deep learning algorithms, cloud computing infrastructure, and proprietary database of 1 trillion chemistries, DeepCure's platform finds drug candidates that deliver improved value to patients. DeepCure's proprietary molecular database, MolDB, is a large medicinal chemistry database that covers over 1 trillion compounds and is expanded on demand to 1 quintillion molecules. These compounds are highly diverse and span most of the chemical space currently accessible to chemists. The trillion compounds cover more than 75% of existing medicinal chemistry compounds, including drugs and current clinical candidates in development, synthesized, or reported by medicinal chemists. In addition, a suite of generative models can expand each selected molecule to a million analogs, expanding the search even further to 1 quintillion (10^18) molecules. MolDB enables the discovery of candidates that don't exist in traditional screening libraries.

DeepCure has raised $46M in total funding across 2 rounds. The company is currently at the A stage. Key investors include Morningside Venture Investments, TLV Partners, Sapir Venture Partners.

DeepCure was founded in 2018 by Kfir Schreiber (Co-founder & CEO).

DeepCure operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Artificial Intelligence, Deep Learning. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals.

DeepCure is based in Rehovot, Israel, Center District. The company also has offices abroad.